109 related articles for article (PubMed ID: 309967)
1. Retinoic acid stimulation of the induction of mouse killer T-cells in allogeneic and syngeneic systems.
Dennert G; Crowley C; Kouba J; Lotan R
J Natl Cancer Inst; 1979 Jan; 62(1):89-94. PubMed ID: 309967
[TBL] [Abstract][Full Text] [Related]
2. Effects of retinoic acid on the immune system: stimulation of T killer cell induction.
Dennert G; Lotan R
Eur J Immunol; 1978 Jan; 8(1):23-9. PubMed ID: 346357
[TBL] [Abstract][Full Text] [Related]
3. The importance of serologically detectable histocompatibility antigens in the induction and effector step of cell-mediated lysis.
Dennert G; Hyman R
Eur J Immunol; 1977 May; 7(5):251-7. PubMed ID: 141372
[TBL] [Abstract][Full Text] [Related]
4. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH
Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322
[TBL] [Abstract][Full Text] [Related]
5. LY-2+ effectors cytotoxic for syngeneic tumor cells: generation by allogeneic stimulation and by supernatants from mixed leukocyte cultures.
Hurrell SM; Zarling JM
J Immunol; 1983 Aug; 131(2):1017-23. PubMed ID: 6223084
[TBL] [Abstract][Full Text] [Related]
6. In vitro induction of polyclonal killer T cells with 2-mercaptoethanol and the essential role of macrophages in this process.
Igarashi T; Okada M; Kishimoto T; Yamamura Y
J Immunol; 1977 May; 118(5):1697-703. PubMed ID: 67145
[TBL] [Abstract][Full Text] [Related]
7. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
8. Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells.
Sensi ML; Parenza M; Parmiani G
J Natl Cancer Inst; 1983 Feb; 70(2):291-7. PubMed ID: 6571938
[TBL] [Abstract][Full Text] [Related]
9. Induction and characterization of minor histocompatibility antigens. Specific primary cytotoxic T lymphocyte responses in vitro.
Ando K; Nakashima I; Nagase F; Isobe K; Kawashima K; Hasegawa Y; Yoshida T; Iwamoto T; Hasegawa T; Muro Y
J Immunol; 1988 Feb; 140(3):723-9. PubMed ID: 2448374
[TBL] [Abstract][Full Text] [Related]
10. Suppression of the cytotoxic response of mouse lymphocytes to syngeneic tumor cells by tumor-promoting phorbol ester.
Fredrickson GG; Bennett M
Cancer Res; 1982 Sep; 42(9):3601-6. PubMed ID: 7105034
[TBL] [Abstract][Full Text] [Related]
11. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor.
Bartik MM; Takesue BY; Mokyr MB
Cancer Res; 1987 Sep; 47(18):4848-55. PubMed ID: 3497711
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
Fuyama S; Yamamoto H; Fujii Y; Arai S
Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
[TBL] [Abstract][Full Text] [Related]
13. Requirements for T cells in alloantigen-induced generation of non-T cell-mediated cytotoxicity against syngeneic mouse sarcoma cells.
Paciucci PA; Macphail S; Bach FH; Zarling JM
J Immunol; 1980 Jul; 125(1):36-9. PubMed ID: 6155401
[TBL] [Abstract][Full Text] [Related]
14. Activation of nonspecific killer cells by interleukin 2-containing supernatants.
Teh HS; Yu M
J Immunol; 1983 Oct; 131(4):1827-33. PubMed ID: 6194216
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
Hinuma S; Naruo K; Shiho O; Tsukamoto K
Immunology; 1986 Oct; 59(2):251-9. PubMed ID: 3490435
[TBL] [Abstract][Full Text] [Related]
16. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.
Glas R; Waldenström M; Höglund P; Klein G; Kärre K; Ljunggren HG
Cancer Res; 1995 May; 55(9):1911-6. PubMed ID: 7728758
[TBL] [Abstract][Full Text] [Related]
17. Loss of reactivity of a BALB/c myeoloma tumor with allogeneic and syngeneic cytotoxic T lymphocytes.
Russel JH; Hale AH; Inbar D; Eisen HN
Eur J Immunol; 1978 Sep; 8(9):640-5. PubMed ID: 309400
[TBL] [Abstract][Full Text] [Related]
18. Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells. An antibody-based mechanism for tumor immunity.
Bright RK; Shearer MH; Kennedy RC
J Immunol; 1994 Sep; 153(5):2064-71. PubMed ID: 8051411
[TBL] [Abstract][Full Text] [Related]
19. In vivo priming of natural killer T cells by dendritic cells pulsed with hepatoma-derived acid-eluted substances.
Ishii R; Shimizu M; Nakagawa Y; Shimizu K; Tanaka S; Takahashi H
Cancer Immunol Immunother; 2004 May; 53(5):383-90. PubMed ID: 14624311
[TBL] [Abstract][Full Text] [Related]
20. T lymphocyte responses to multiple minor histocompatibility antigens generate both self-major histocompatibility complex-restricted and cross-reactive cytotoxic T lymphocytes.
Tremblay N; Fontaine P; Perreault C
Transplantation; 1994 Jul; 58(1):59-67. PubMed ID: 8036709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
